Embecta Corp. reported fiscal second‑quarter 2026 revenue of $221.8 million, a decline from $261 million in the prior quarter and a 14.4% year‑over‑year drop. Non‑GAAP earnings per share were $0.27, falling short of the consensus estimate of $0.42 and resulting in a net loss of $4.1 million, compared with a $23.5 million net income in Q2 2025.
Revenue decline was driven largely by a 29.4% year‑over‑year drop in U.S. sales, the company’s largest market. Gross margin contracted to 57.6% from 63.4% in the prior year, while adjusted gross profit margin fell to 59.4% from 63.7%. The margin compression reflects lower volumes and pricing pressure in the pen‑needle segment.
Management cut its full‑year 2026 outlook. Revenue guidance was lowered to $1,015–$1,035 million from $1,071–$1,093 million; adjusted EPS guidance was reduced to $1.55–$1.75 from $2.80–$3.00; and operating‑margin guidance was trimmed to 22.25%–23.25% from 29%–30%.
In a statement, President and CEO Devdatt Kurdikar said the guidance “assumes uncertainty around pen‑needle market volume estimates, and it is ‘not possible to exactly calculate’ individual contributions.” He also highlighted supply risk in alcohol swabs, noting that “our sole supplier… exited” and “we were unable to qualify an alternate supplier under applicable FDA standards.” Management framed the quarter as a “reset driven by U.S. pen‑needle share loss and retail market softness.”
Investors reacted negatively to the earnings, citing the significant miss on revenue and EPS, the sharp downward revision of full‑year guidance, the decline in U.S. sales, and margin compression. The company also announced a $100 million share‑repurchase program, a reduction of its quarterly dividend from $0.15 to $0.01, and the ongoing acquisition of Owen Mumford, which is expected to add about $30 million in revenue in fiscal 2026 but will dilute adjusted EPS by roughly $0.15.
The results underscore the challenges facing Embecta’s core pen‑needle business and signal a strategic shift toward diversifying its product portfolio and strengthening its U.S. market presence. The company’s guidance reflects a cautious outlook amid competitive pressures and supply‑chain uncertainties, while its capital‑allocation decisions aim to preserve liquidity and support long‑term growth.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.